Diode laser trans‐scleral cyclophotocoagulation in refractory glaucoma treatment

Montanari, P.; Marangoni, P; Pinotti, D.; Miglior, M

doi:10.1111/j.1600-0420.1997.tb00468.x

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Four cases of sympathetic ophthalmia have been reported following TSCPC . In the extended literature search conducted, we identified 5979 eyes (6049 eyes including the current study) that had undergone diode laser TSCPC . If we include all cases of diode laser TSCPC reported in the literature (including the current study), the incidence is estimated at one in 1512, or 0.07% (95% CI 0.03%–0.17%).…”

Section: Discussionmentioning

confidence: 99%

Incidence of hypotony and sympathetic ophthalmia following trans‐scleral cyclophotocoagulation for glaucoma and a report of risk factors

Aujla

Lee

Vincent

et al. 2013

Clinical Exper Ophthalmology

View full text Add to dashboard Cite

Total laser energy is one of several risk factors that act in a sufficient component cause-model to produce hypotony in an individual patient. The small sample size precluded inference for other individual putative risk factors but titrating laser energy may help decrease the occurrence of hypotony. The risk of sympathetic ophthalmia calculated from the literature is likely an overestimate caused by publication bias.

show abstract

Section: Discussionmentioning

confidence: 99%

Incidence of hypotony and sympathetic ophthalmia following trans‐scleral cyclophotocoagulation for glaucoma and a report of risk factors

Aujla

Lee

Vincent

et al. 2013

Clinical Exper Ophthalmology

View full text Add to dashboard Cite

show abstract

Cyclodestructive procedures for non-refractory glaucoma

Chen

Kim

Coleman

2018

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Background Glaucoma is a leading cause of blindness worldwide. It results in a progressive loss of peripheral vision and, in late stages, loss of central vision leading to blindness. Early treatment of glaucoma aims to prevent or delay vision loss. Elevated intraocular pressure (IOP) is the main causal modifiable risk factor for glaucoma. Aqueous outflow obstruction is the main cause of IOP elevation, which can be mitigated either by increasing outflow or reducing aqueous humor production. Cyclodestructive procedures use various methods to target and destroy the ciliary body epithelium, the site of aqueous humor production, thereby lowering IOP. The most common approach is laser cyclophotocoagulation. Objectives To assess the effectiveness and safety of cyclodestructive procedures for the management of non-refractory glaucoma (i.e. glaucoma in an eye that has not undergone incisional glaucoma surgery). We also aimed to compare the effect of different routes of administration, laser delivery instruments, and parameters of cyclophotocoagulation with respect to IOP control, visual acuity, pain control, and adverse events. Search methods We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Trials Register) (2017, Issue 8); Ovid MEDLINE; Embase.com; LILACS; the metaRegister of Controlled Trials (mRCT) and ClinicalTrials.gov . The date of the search was 7 August 2017. We also searched the reference lists of reports from included studies. Selection criteria We included randomized controlled trials of participants who had undergone cyclodestruction as a primary treatment for glaucoma. We included only head-to-head trials that had compared cyclophotocoagulation to other procedural interventions, or compared cyclophotocoagulation using different types of lasers, delivery methods, parameters, or a combination of these factors. Data collection and analysis Two review authors independently screened search results, assessed risks of bias, extracted data, and graded the certainty of the evidence in accordance with Cochrane standards. Main results We included one trial (92 eyes of 92 participants) that evaluated the efficacy of diode transscleral cyclophotocoagulation (TSCPC) as primary surgical therapy. We identified no other eligible ongoing or completed trial. The included trial compared low-energy versus high-energy TSCPC in eyes with primary open-angle glaucoma. The trial was conducted in Ghana and had a mean follow-up period of 13.2 months post-treatment. In this trial, low-energy TSCPC was defined as 45.0 J delivered, high-energy as 65.5 J delivered; it is worth noting that other trials have defined high- and low-energy TSCPC differently. We assessed this trial to have had low risk of selection bias and reporting bias, unclear risk of performance bias, and high risk of detection bias and attrition bias. Trial authors excluded 13 participants with missing follow-up data; the analyses therefore included 40 (85%) of 47 participants in the low-energy ...

show abstract

Cyclodiode laser therapy for painful, blind glaucomatous eyes

Martin

2001

British Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

Diode laser trans‐scleral cyclophotocoagulation in refractory glaucoma treatment

Cited by 3 publications

References 0 publications

Incidence of hypotony and sympathetic ophthalmia following trans‐scleral cyclophotocoagulation for glaucoma and a report of risk factors

Incidence of hypotony and sympathetic ophthalmia following trans‐scleral cyclophotocoagulation for glaucoma and a report of risk factors

Cyclodestructive procedures for non-refractory glaucoma

Cyclodiode laser therapy for painful, blind glaucomatous eyes

Contact Info

Product

Resources

About